Skip to main content

Table 9 The summary of sensitivity analyses

From: Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

Outcomes

Finerenone

SGLT-2i

GLP-1 RA

Comparison

Risk ratio

95%Cl

I2(%)

P

I

C

I

C

I

C

MACE

6519

6507

12,959

11,595

6045

5344

SGLT-2i vs placebo

0.84

0.78–0.91

23.0

0.199

      

GLP-1 RA vs placebo

0.86

0.78–0.94

  
      

Finerenone vs placebo

0.88

0.80–0.97

  
      

GLP-1 RA vs SGLT-2i

1.02

0.90–1.15

  
      

Finerenone vs SGLT-2i

1.05

0.93–1.18

  
      

Finerenone vs GLP-1 RA

1.03

0.90–1.17

  

Renal outcome

7234

6600

11,547

10,888

3754

3780

SGLT-2i vs placebo

0.66

0.59–0.73

39.2

0.079

      

GLP-1 RA vs placebo

0.90

0.80–1.02

  
      

Finerenone vs placebo

0.86

0.79–0.93

  
      

GLP-1 RA vs SGLT-2i

1.37

1.17–1.61

  
      

Finerenone vs SGLT-2i

1.30

1.14–1.49

  
      

Finerenone vs GLP-1 RA

0.95

0.82–1.10

  

HHF

6519

6507

12,960

11,596

2673

2662

SGLT-2i vs placebo

0.60

0.53–0.68

49.9

0.030

      

GLP-1 RA vs placebo

0.90

0.73–1.09

  
      

Finerenone vs placebo

0.79

0.67–0.92

  
      

GLP-1 RA vs SGLT-2i

1.49

1.18–1.89

  
      

Finerenone vs SGLT-2i

1.31

1.07–1.61

  
      

Finerenone vs GLP-1 RA

0.88

0.68–1.14

  

ACD

6519

6507

11,944

10,805

2673

2662

SGLT-2i vs placebo

0.90

0.81–0.99

0.0

0.537

      

GLP-1 RA vs placebo

0.89

0.77–1.02

  
      

Finerenone vs placebo

0.90

0.80–1.00

  
      

GLP-1 RA vs SGLT-2i

0.99

0.83–1.17

  
      

Finerenone vs SGLT-2i

1.00

0.86–1.16

  
      

Finerenone vs GLP-1 RA

1.01

0.85–1.20

  

CVD

6519

6507

12,960

11,596

2673

2662

SGLT-2i vs placebo

0.87

0.78–0.97

0.0

0.658

      

GLP-1 RA vs placebo

0.90

0.75–1.08

  
      

Finerenone vs placebo

0.88

0.76–1.02

  
      

GLP-1 RA vs SGLT-2i

1.04

0.84–1.28

  
      

Finerenone vs SGLT-2i

1.02

0.85–1.22

  
      

Finerenone vs GLP-1 RA

0.98

0.78–1.23

  
  1. I intervention, C control
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840